Association of IVIG Plus Methylprednisolone With Persistent or Recurrent Fever in Children With MIS-C | Critical Care Medicine | JN Learning | AMA Ed Hub [Skip to Content]
[Skip to Content Landing]

Association of Intravenous Immunoglobulins Plus Methylprednisolone vs Immunoglobulins Alone With Course of Fever in Multisystem Inflammatory Syndrome in Children

Educational Objective
To identify the key insights or developments described in this article
1 Credit CME
Key Points

Question  Is there an association between treatment with intravenous immunoglobulins (IVIG) plus methylprednisolone vs IVIG alone and course of fever in multisystem inflammatory syndrome in children (MIS-C) associated with severe acute respiratory syndrome coronavirus 2?

Findings  This retrospective cohort study included 111 children with MIS-C. After propensity score matching, the rate of treatment failure (defined by the persistence of fever 2 days after the introduction of first-line therapy or recrudescence of fever within 7 days) for those who received IVIG plus methylprednisolone vs IVIGs alone was 9% vs 51%, a difference that was statistically significant.

Meaning  Combined treatment with methylprednisolone vs IVIG alone was associated with a better course of fever in MIS-C.

Abstract

Importance  Multisystem inflammatory syndrome in children (MIS-C) is the most severe pediatric disease associated with severe acute respiratory syndrome coronavirus 2 infection, potentially life-threatening, but the optimal therapeutic strategy remains unknown.

Objective  To compare intravenous immunoglobulins (IVIG) plus methylprednisolone vs IVIG alone as initial therapy in MIS-C.

Design, Setting, and Participants  Retrospective cohort study drawn from a national surveillance system with propensity score–matched analysis. All cases with suspected MIS-C were reported to the French National Public Health Agency. Confirmed MIS-C cases fulfilling the World Health Organization definition were included. The study started on April 1, 2020, and follow-up ended on January 6, 2021.

Exposures  IVIG and methylprednisolone vs IVIG alone.

Main Outcomes and Measures  The primary outcome was persistence of fever 2 days after the introduction of initial therapy or recrudescence of fever within 7 days, which defined treatment failure. Secondary outcomes included a second-line therapy, hemodynamic support, acute left ventricular dysfunction after first-line therapy, and length of stay in the pediatric intensive care unit. The primary analysis involved propensity score matching with a minimum caliper of 0.1.

Results  Among 181 children with suspected MIS-C, 111 fulfilled the World Health Organization definition (58 females [52%]; median age, 8.6 years [interquartile range, 4.7 to 12.1]). Five children did not receive either treatment. Overall, 3 of 34 children (9%) in the IVIG and methylprednisolone group and 37 of 72 (51%) in the IVIG alone group did not respond to treatment. Treatment with IVIG and methylprednisolone vs IVIG alone was associated with lower risk of treatment failure (absolute risk difference, −0.28 [95% CI, −0.48 to −0.08]; odds ratio [OR], 0.25 [95% CI, 0.09 to 0.70]; P = .008). IVIG and methylprednisolone therapy vs IVIG alone was also significantly associated with lower risk of use of second-line therapy (absolute risk difference, −0.22 [95% CI, −0.40 to −0.04]; OR, 0.19 [95% CI, 0.06 to 0.61]; P = .004), hemodynamic support (absolute risk difference, −0.17 [95% CI, −0.34 to −0.004]; OR, 0.21 [95% CI, 0.06 to 0.76]), acute left ventricular dysfunction occurring after initial therapy (absolute risk difference, −0.18 [95% CI, −0.35 to −0.01]; OR, 0.20 [95% CI, 0.06 to 0.66]), and duration of stay in the pediatric intensive care unit (median, 4 vs 6 days; difference in days, −2.4 [95% CI, −4.0 to −0.7]).

Conclusions and Relevance  Among children with MIS-C, treatment with IVIG and methylprednisolone vs IVIG alone was associated with a more favorable fever course. Study interpretation is limited by the observational design.

Sign in to take quiz and track your certificates

Buy This Activity

JN Learning™ is the home for CME and MOC from the JAMA Network. Search by specialty or US state and earn AMA PRA Category 1 CME Credit™ from articles, audio, Clinical Challenges and more. Learn more about CME/MOC

Article Information

Corresponding Author: François Angoulvant, MD, PhD, Paediatric Emergency Department, Necker-Enfants Malades University Hospital, 149 Rue de Sèvre, 75015 Paris, France (francois.angoulvant@aphp.fr).

Accepted for Publication: January 19, 2021.

Published Online: February 1, 2021. doi:10.1001/jama.2021.0694

Correction: This article was corrected on July 6, 2021, to add the list of nonauthor collaborators as a supplement.

Author Contributions: Drs Ouldali and Angoulvant had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

Concept and design: Ouldali, Lachaume, M. Levy, C. Levy, Angoulvant.

Acquisition, analysis, or interpretation of data: Ouldali, Toubiana, Antona, Javouhey, Madhi, Lorrot, Léger, Galeotti, Claude, Wiedemann, Ovaert, Dumortier, Kahn, Mandelcwajg, Percheron, Biot, Bordet, Girardin, Yang, Grimaud, Oualha, Allali, Bajolle, Beyler, Meinzer, M. Levy, Paulet, C. Levy, Cohen, Belot, Angoulvant.

Drafting of the manuscript: Ouldali, Mandelcwajg, Yang, Angoulvant.

Critical revision of the manuscript for important intellectual content: All authors.

Statistical analysis: Ouldali, Bordet, Angoulvant.

Obtained funding: C. Levy, Belot.

Administrative, technical, or material support: Toubiana, Antona, Javouhey, Lachaume, Dumortier, Mandelcwajg, Girardin, Allali, Meinzer, Paulet, C. Levy, Belot, Angoulvant.

Supervision: Ouldali, Madhi, Mandelcwajg, Girardin, Bajolle, Beyler, C. Levy, Cohen, Belot, Angoulvant.

Conflict of Interest Disclosures: Dr Javouhey reported receiving grants from CSL Behring. Dr C. Levy reported receiving grants from GlaxoSmithKline, Merck Sharp & Dohme, and Sanofi and personal fees from Pfizer and Merck. Dr Cohen reported receiving personal fees from GlaxoSmithKline, Pfizer, Sanofi, and Merck Sharp & Dohme. No other disclosures were reported.

Funding/Support: This study received an unrestricted grant from Pfizer; the French Covid-19 Paediatric Inflammation Consortium received an unrestricted grant from the Square Foundation (Grandir–Fonds de Solidarité Pour L’enfance).

Role of the Funder/Sponsor: The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Group Information: A list of members in the French Covid-19 Pediatric Inflammation Consortium is in Supplement 2.

Additional Contributions: We are grateful to Santé Publique France, Société Française de Pédiatrie, Groupe de Paediatrie Generale, Groupe de Pathologie Infectieuse Pédiatrique, Groupe Francophone de Réanimation et d’Urgences Pédiatriques, Société Française de Cardiologie, Filiale de Cardiologie Pédiatrique et Congénitale, Société Francophone Dédiée à L’étude des Maladies Inflammatoires Pédiatriques, and Filière de Santé des Maladies Auto-immunes et Auto-inflammatoires Rares for their participation in the French Covid-19 Paediatric Inflammation Consortium study. We thank Isabelle Ramay, BSc, Claire Prieur, BSc, Marine Borg, Aurore Prieur, BSc, Laura Meyet, LLM, Jéremy Levy, BSc, Stéphane Bechet, MSc, and Sofia Abbou, LLM, from ACTIV (Association Clinique et Thérapeutique Infantile du Val-de-Marne), Créteil, France; Cecile Hoffart, MSc, and Maxime Brussieux, BSc, from Clinical Research Centre, Centre Hospitalier Intercommunal de Créteil, Créteil, France; Daniel Levy-Bruhl, MD, Mireille Allemand, Scarlett Georges, BSc, Valerie Olie, PhD, Nolween Regnault, PhD, and Jerome Naud, PharmD, from Santé Publique France, Agence Nationale de Santé Publique, Saint-Maurice; Murielle Herasse, PhD, from Filière de Santé Des Maladies Auto-immunes et Auto-inflammatoires Rares (FAI2R), Lyon, France; and David Skurnik, PhD, from INSERM U1151-Equipe 11. We are grateful to every microbiological laboratory staff member who performed severe acute respiratory syndrome coronavirus 2 reverse transcriptase–polymerase chain reaction and antibody testing in each center. None of the persons listed here received compensation for their role in the study.

References
1.
Wu  Z , McGoogan  JM .  Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention.   JAMA. 2020;323(13):1239-1242. doi:10.1001/jama.2020.2648 PubMedGoogle ScholarCrossref
2.
Whittaker  E , Bamford  A , Kenny  J ,  et al; PIMS-TS Study Group and EUCLIDS and PERFORM Consortia.  Clinical characteristics of 58 children with a pediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2.   JAMA. 2020;324(3):259-269. doi:10.1001/jama.2020.10369 PubMedGoogle ScholarCrossref
3.
Toubiana  J , Poirault  C , Corsia  A ,  et al.  Kawasaki-like multisystem inflammatory syndrome in children during the covid-19 pandemic in Paris, France: prospective observational study.   BMJ. 2020;369:m2094. doi:10.1136/bmj.m2094 PubMedGoogle Scholar
4.
Feldstein  LR , Rose  EB , Horwitz  SM ,  et al; Overcoming COVID-19 Investigators; CDC COVID-19 Response Team.  Multisystem inflammatory syndrome in US children and adolescents.   N Engl J Med. 2020;383(4):334-346. doi:10.1056/NEJMoa2021680PubMedGoogle ScholarCrossref
5.
Belot  A , Antona  D , Renolleau  S ,  et al.  SARS-CoV-2-related paediatric inflammatory multisystem syndrome, an epidemiological study, France, 1 March to 17 May 2020.   Euro Surveill. 2020;25(22). doi:10.2807/1560-7917.ES.2020.25.22.2001010 PubMedGoogle Scholar
6.
Dufort  EM , Koumans  EH , Chow  EJ ,  et al; New York State and Centers for Disease Control and Prevention Multisystem Inflammatory Syndrome in Children Investigation Team.  Multisystem inflammatory syndrome in children in New York state.   N Engl J Med. 2020;383(4):347-358. doi:10.1056/NEJMoa2021756 PubMedGoogle ScholarCrossref
7.
Centers for Disease Control and Prevention. Multisystem inflammatory syndrome in children (MIS-C) associated with coronavirus disease 2019 (COVID-19). Published May 14, 2020. Accessed January 19, 2021. https://emergency.cdc.gov/han/2020/han00432.asp
8.
European Centre for Disease Prevention and Control. Rapid risk assessment: paediatric inflammatory multisystem syndrome and SARS-CoV-2 infection in children. Published May 15, 2020. Accessed January 19, 2021. https://www.ecdc.europa.eu/en/publications-data/paediatric-inflammatory-multisystem-syndrome-and-sars-cov-2-rapid-risk-assessment
9.
Belhadjer  Z , Méot  M , Bajolle  F ,  et al.  Acute heart failure in multisystem inflammatory syndrome in children in the context of global SARS-CoV-2 pandemic.   Circulation. 2020;142(5):429-436. doi:10.1161/CIRCULATIONAHA.120.048360 PubMedGoogle ScholarCrossref
10.
Jiang  L , Tang  K , Levin  M ,  et al.  COVID-19 and multisystem inflammatory syndrome in children and adolescents.   Lancet Infect Dis. 2020;20(11):e276-e288. doi:10.1016/S1473-3099(20)30651-4 PubMedGoogle ScholarCrossref
11.
Pouletty  M , Borocco  C , Ouldali  N ,  et al.  Paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 mimicking Kawasaki disease (Kawa-COVID-19): a multicentre cohort.   Ann Rheum Dis. 2020;79(8):999-1006. doi:10.1136/annrheumdis-2020-217960 PubMedGoogle ScholarCrossref
12.
Felsenstein  S , Willis  E , Lythgoe  H ,  et al.  Presentation, treatment response and short-term outcomes in paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 (PIMS-TS).   J Clin Med. 2020;9(10):E3293. doi:10.3390/jcm9103293 PubMedGoogle Scholar
13.
Henderson  LA , Canna  SW , Friedman  KG ,  et al.  American College of Rheumatology clinical guidance for multisystem inflammatory syndrome in children associated with SARS-CoV-2 and hyperinflammation in pediatric COVID-19: version 1.   Arthritis Rheumatol. 2020;72(11):1791-1805. doi:10.1002/art.41454 PubMedGoogle ScholarCrossref
14.
Harwood  R , Allin  B , Jones  CE ,  et al; PIMS-TS National Consensus Management Study Group.  A national consensus management pathway for paediatric inflammatory multisystem syndrome temporally associated with COVID-19 (PIMS-TS): results of a national Delphi process.   Lancet Child Adolesc Health. 2020;S2352-4642(20)30304-7. doi:10.1016/S2352-4642(20)30304-7 PubMedGoogle Scholar
15.
Belot  A , Levy-Bruhl  D ; French Covid-19 Pediatric Inflammation Consortium.  Multisystem inflammatory syndrome in children in the United States.   N Engl J Med. 2020;383(18):1793-1794. doi:10.1056/NEJMc2026136 PubMedGoogle Scholar
16.
Connexion à COVID-19 inflammation pédiatrique. Accessed November 11, 2020. https://voozanoo.santepubliquefrance.fr//1851260971/scripts/newrec.php
17.
Ouldali  N , Yang  DD , Madhi  F ,  et al; investigator group of the PANDOR study.  Factors associated with severe SARS-CoV-2 infection.   Pediatrics. 2020;e2020023432. doi:10.1542/peds.2020-023432 PubMedGoogle Scholar
18.
World Health Organization. Multisystem inflammatory syndrome in children and adolescents temporally related to COVID-19. Accessed August 27, 2020. https://www.who.int/news-room/commentaries/detail/multisystem-inflammatory-syndrome-in-children-and-adolescents-with-covid-19
19.
Koné-Paut  I , Tellier  S , Belot  A ,  et al.  Phase II open-label study of anakinra in intravenous immunoglobulin-resistant Kawasaki disease.   Arthritis Rheumatol. 2020. doi:10.1002/art.41481PubMedGoogle Scholar
20.
Wallace  CA , French  JW , Kahn  SJ , Sherry  DD .  Initial intravenous gammaglobulin treatment failure in Kawasaki disease.   Pediatrics. 2000;105(6):E78. doi:10.1542/peds.105.6.e78 PubMedGoogle Scholar
21.
McCrindle  BW , Rowley  AH , Newburger  JW ,  et al; American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee of the Council on Cardiovascular Disease in the Young; Council on Cardiovascular and Stroke Nursing; Council on Cardiovascular Surgery and Anesthesia; and Council on Epidemiology and Prevention.  Diagnosis, treatment, and long-term management of Kawasaki disease: a scientific statement for health professionals from the American Heart Association.   Circulation. 2017;135(17):e927-e999. doi:10.1161/CIR.0000000000000484 PubMedGoogle ScholarCrossref
22.
Haute Autorité de Santé. Guidance leaflet: management of fever in children. Published October 2016. Accessed January 19, 2021. https://www.has-sante.fr/upload/docs/application/pdf/2017-03/dir5/guidance_leaflet_management_of_fever_in_children.pdf
23.
Haukoos  JS , Lewis  RJ .  The propensity score.   JAMA. 2015;314(15):1637-1638. doi:10.1001/jama.2015.13480 PubMedGoogle ScholarCrossref
24.
Thomas  L , Li  F , Pencina  M .  Using propensity score methods to create target populations in observational clinical research.   JAMA. 2020;323(5):466-467. doi:10.1001/jama.2019.21558 PubMedGoogle ScholarCrossref
25.
Basagaña  X , Pedersen  M , Barrera-Gómez  J ,  et al; ESCAPE Birth Outcomes working group.  Analysis of multicentre epidemiological studies: contrasting fixed or random effects modelling and meta-analysis.   Int J Epidemiol. 2018;47(4):1343-1354. doi:10.1093/ije/dyy117 PubMedGoogle ScholarCrossref
26.
Nguyen  T-L , Collins  GS , Spence  J ,  et al.  Comparison of the ability of double-robust estimators to correct bias in propensity score matching analysis: a Monte Carlo simulation study.   Pharmacoepidemiol Drug Saf. 2017;26(12):1513-1519. doi:10.1002/pds.4325 PubMedGoogle ScholarCrossref
27.
McIntosh  AM , Tong  S , Deakyne  SJ , Davidson  JA , Scott  HF .  Validation of the vasoactive-inotropic score in pediatric sepsis.   Pediatr Crit Care Med. 2017;18(8):750-757. doi:10.1097/PCC.0000000000001191 PubMedGoogle ScholarCrossref
28.
Wang  R , Ware  JH .  Detecting moderator effects using subgroup analyses.   Prev Sci. 2013;14(2):111-120. doi:10.1007/s11121-011-0221-x PubMedGoogle ScholarCrossref
29.
Belhadjer  Z , Auriau  J , Méot  M ,  et al.  Addition of corticosteroids to immunoglobulins is associated with recovery of cardiac function in multi-inflammatory syndrome in children.   Circulation. 2020;142(23):2282-2284. doi:10.1161/CIRCULATIONAHA.120.050147 PubMedGoogle ScholarCrossref
30.
Jonat  B , Gorelik  M , Boneparth  A ,  et al.  Multisystem inflammatory syndrome in children associated with coronavirus disease 2019 in a children’s hospital in New York City: patient characteristics and an institutional protocol for evaluation, management, and follow-up.   Pediatr Crit Care Med. 2020. doi:10.1097/PCC.0000000000002598 PubMedGoogle Scholar
31.
Rowley  AH .  Understanding SARS-CoV-2-related multisystem inflammatory syndrome in children.   Nat Rev Immunol. 2020;20(8):453-454. doi:10.1038/s41577-020-0367-5 PubMedGoogle ScholarCrossref
32.
Arditi  M , Bahar  I .  Multisystem inflammatory syndrome in children in the United States.   N Engl J Med. 2020;383(18):1794. doi:10.1056/NEJMc2026136PubMedGoogle Scholar
33.
Horby  P , Lim  WS , Emberson  JR ,  et al; RECOVERY Collaborative Group.  Dexamethasone in hospitalized patients with COVID-19: preliminary report.   N Engl J Med. 2020. doi:10.1056/NEJMoa2021436PubMedGoogle Scholar
34.
Sterne  JAC , Murthy  S , Diaz  JV ,  et al; WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group.  Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis.   JAMA. 2020;324(13):1330-1341. doi:10.1001/jama.2020.17023 PubMedGoogle Scholar
35.
Levin  M .  Childhood multisystem inflammatory syndrome: a new challenge in the pandemic.   N Engl J Med. 2020;383(4):393-395. doi:10.1056/NEJMe2023158 PubMedGoogle ScholarCrossref
36.
Bordet  J , Perrier  S , Olexa  C , Gerout  A-C , Billaud  P , Bonnemains  L .  Paediatric multisystem inflammatory syndrome associated with COVID-19: filling the gap between myocarditis and Kawasaki?   Eur J Pediatr. 2020. doi:10.1007/s00431-020-03807-0 PubMedGoogle Scholar
If you are not a JN Learning subscriber, you can either:
Subscribe to JN Learning for one year
Buy this activity
jn-learning_Modal_Multimedia_LoginSubscribe_Purchase
Close
If you are not a JN Learning subscriber, you can either:
Subscribe to JN Learning for one year
Buy this activity
jn-learning_Modal_Multimedia_LoginSubscribe_Purchase
Close
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Education Center Collection Sign In Modal Right
Close

Name Your Search

Save Search
Close
With a personal account, you can:
  • Track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
jn-learning_Modal_SaveSearch_NoAccess_Purchase
Close

Lookup An Activity

or

Close

My Saved Searches

You currently have no searches saved.

Close
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Education Center Collection Sign In Modal Right
Close